CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
ADX-629drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04908514
NCT04908514Phase 2Completed
CompareCT.gov

A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Plaque Psoriasis

Aldeyra Therapeutics, Inc.·interventional·Posted Jun 1, 2021·Updated Mar 11, 2025

In Brief

A Phase 2 clinical trial evaluating ADX-629 for Plaque Psoriasis. Completed, enrolled 10 participants across 1 site.

Detailed Summary

A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJun 1, 2021
Enrollment StartMay 7, 2021
Primary CompletionJan 21, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.1 years ago

Interventions

ADX-629drug

ADX-629 administered orally twice daily (BID) for approximately 12 weeks.